OBIO vs. TMCI, NPCE, OM, CLPT, NNOX, ZIMV, SNWV, CATX, NYXH, and DRTS
Should you be buying Orchestra BioMed stock or one of its competitors? The main competitors of Orchestra BioMed include Treace Medical Concepts (TMCI), NeuroPace (NPCE), Outset Medical (OM), ClearPoint Neuro (CLPT), Nano-X Imaging (NNOX), ZimVie (ZIMV), Sanuwave Health (SNWV), Perspective Therapeutics (CATX), Nyxoah (NYXH), and Alpha Tau Medical (DRTS). These companies are all part of the "medical equipment" industry.
Orchestra BioMed vs. Its Competitors
Treace Medical Concepts (NASDAQ:TMCI) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.
Treace Medical Concepts has higher revenue and earnings than Orchestra BioMed. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.
84.1% of Treace Medical Concepts shares are owned by institutional investors. Comparatively, 53.6% of Orchestra BioMed shares are owned by institutional investors. 27.7% of Treace Medical Concepts shares are owned by company insiders. Comparatively, 8.1% of Orchestra BioMed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Treace Medical Concepts currently has a consensus target price of $10.16, indicating a potential upside of 67.86%. Orchestra BioMed has a consensus target price of $14.20, indicating a potential upside of 390.50%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, analysts clearly believe Orchestra BioMed is more favorable than Treace Medical Concepts.
In the previous week, Treace Medical Concepts and Treace Medical Concepts both had 1 articles in the media. Treace Medical Concepts' average media sentiment score of 1.84 beat Orchestra BioMed's score of -0.77 indicating that Treace Medical Concepts is being referred to more favorably in the media.
Treace Medical Concepts has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Orchestra BioMed has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.
Treace Medical Concepts has a net margin of -25.14% compared to Orchestra BioMed's net margin of -2,297.85%. Treace Medical Concepts' return on equity of -48.69% beat Orchestra BioMed's return on equity.
Summary
Treace Medical Concepts beats Orchestra BioMed on 10 of the 16 factors compared between the two stocks.
Get Orchestra BioMed News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Orchestra BioMed Competitors List
Related Companies and Tools
This page (NASDAQ:OBIO) was last updated on 7/4/2025 by MarketBeat.com Staff
Free OBIO Stock Alerts